Trial · NCT02409342
A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
NCT02409342, Phase 3, Completed, Hoffmann-La Roche; results first posted 2021-02-18
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]. Trials, record NCT02409342. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02409342
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
- NCT number
- NCT02409342
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 572 participants, actual
- Lead sponsor
- Hoffmann-La Roche
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
- Interventions
- Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody, Carboplatin, Cisplatin, Gemcitabine, Pemetrexed
- First posted
- 2015-04-06
- Last updated
- 2023-03-15
- Other registries' IDs
- eudract:2014-003083-21
- Results first posted
- 2021-02-18
Source ClinicalTrials.gov
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival (OS) in the TC3 or IC3-WT Populations | From randomization to death from any cause until data cut-off on 10 September 2018 (up to approximately 38 months) | OS is defined as the time from randomization to death from any cause. |
| Primary | Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | From randomization to death from any cause until data cut-off on 4 February 2020 (up to approximately 54.5 months) | OS is defined as the time from randomization to death from any cause. |
| Secondary | Progression-free Survival (PFS) in the TC3 or IC3-WT Populations | From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months) | PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first. PFS could not be formally tested. |
| Secondary | Progression-free Survival (PFS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 4 February 2020 (up to approximately 54.5 months) | PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first. PFS could not be formally tested. |
| Secondary | Percentage of Participants With Objective Response (ORR) in the TC3 or IC3-WT Populations | Every 6 weeks for 48 weeks following Day 1, thereafter every 9 weeks after completion of Week 48 tumor assessment, regardless of treatment delays, until radiographic disease progression until data cut-off on 10 Sep 2018 (up to approximately 38 months) | Objective response (partial response plus complete response) as determined by the investigator according to RECIST v1.1. |
| Secondary | Percentage of Participants With Objective Response (ORR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Every 6 weeks for 48 weeks following Day 1, thereafter every 9 weeks after completion of Week 48 tumor assessment, regardless of treatment delays, until radiographic disease progression until data cut-off on 4 Feb 2020 (up to approximately 54.5 months) | Objective response (partial response plus complete response) as determined by the investigator according to RECIST v1.1. |
| Secondary | Duration of Response (DOR) in the TC3 or IC3-WT Populations | From first occurrence of a complete response or partial response, whichever occurs first, until first date that progressive disease or death is documented, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months) | DOR is defined as the time from the first occurrence of a documented objective response to the time of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first. |
| Secondary | Duration of Response (DOR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | From first occurrence of a complete response or partial response, whichever occurs first, until first date that progressive disease or death is documented, whichever occurs first until data cut-off on 4 February 2020 (up to approximately 54.5 months) | DOR is defined as the time from the first occurrence of a documented objective response to the time of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first. |
| Secondary | Percentage of Participants Who Are Alive at 1 Year in the TC3 or IC3-WT Populations | Baseline to 1 year or death, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months) | |
| Secondary | Percentage of Participants Who Are Alive at 2 Years in the TC3 or IC3-WT Populations | Baseline to 2 years or death, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months) |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 registered outcomesOutcomes23
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Survival (OS) in the TC3 or IC3-WT Populations | From randomization to death from any cause until data cut-off on 10 September 2018 (up to approximately 38 months) | Analysis was performed for the TC3 or IC3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \[WT\]). | Months | MEDIAN |
| PRIMARY | Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | From randomization to death from any cause until data cut-off on 4 February 2020 (up to approximately 54.5 months) | Analysis was performed for the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \[WT\]). | Months | MEDIAN |
| SECONDARY | Progression-free Survival (PFS) in the TC3 or IC3-WT Populations | From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months) | Analysis was performed for the TC3 or IC3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \[WT\]). | Months | NUMBER |
| SECONDARY | Progression-free Survival (PFS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 4 February 2020 (up to approximately 54.5 months) | Analysis was performed for the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \[WT\]). | Months | NUMBER |
| SECONDARY | Percentage of Participants With Objective Response (ORR) in the TC3 or IC3-WT Populations | Every 6 weeks for 48 weeks following Day 1, thereafter every 9 weeks after completion of Week 48 tumor assessment, regardless of treatment delays, until radiographic disease progression until data cut-off on 10 Sep 2018 (up to approximately 38 months) | Analysis was performed for the TC3 or IC3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \[WT\]). | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Objective Response (ORR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Every 6 weeks for 48 weeks following Day 1, thereafter every 9 weeks after completion of Week 48 tumor assessment, regardless of treatment delays, until radiographic disease progression until data cut-off on 4 Feb 2020 (up to approximately 54.5 months) | Analysis was performed for the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \[WT\]). | Percentage of participants | NUMBER |
| SECONDARY | Duration of Response (DOR) in the TC3 or IC3-WT Populations | From first occurrence of a complete response or partial response, whichever occurs first, until first date that progressive disease or death is documented, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months) | Analysis was performed for the TC3 or IC3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \[WT\]). | Months | NUMBER |
| SECONDARY | Duration of Response (DOR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | From first occurrence of a complete response or partial response, whichever occurs first, until first date that progressive disease or death is documented, whichever occurs first until data cut-off on 4 February 2020 (up to approximately 54.5 months) | Analysis was performed for the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \[WT\]). | Months | NUMBER |
| SECONDARY | Percentage of Participants Who Are Alive at 1 Year in the TC3 or IC3-WT Populations | Baseline to 1 year or death, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months) | Analysis was performed for the TC3 or IC3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \[WT\]). | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Who Are Alive at 2 Years in the TC3 or IC3-WT Populations | Baseline to 2 years or death, whichever occurs first until data cut-off on 10 September 2018 (up to approximately 38 months) | Analysis was performed for the TC3 or IC3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \[WT\]). | Percentage of participants | NUMBER |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 outcomesResults by group741
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) in the TC3 or IC3-WT Populations | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 13.1 | 95% Confidence Interval 7.4 to 16.5 | Months | |
| Overall Survival (OS) in the TC3 or IC3-WT Populations | Atezolizumab | 20.2 | 95% Confidence Interval 16.5 to NA | Months | |
| Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | TC2/3 or IC2/3-WT Population | 16.1 | 95% Confidence Interval 12.6 to 18.0 | Months |
| Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Atezolizumab | TC2/3 or IC2/3-WT Population | 19.9 | 95% Confidence Interval 17.2 to 25.3 | Months |
| Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | TC1/2/3 or IC1/2/3-WT Population | 14.7 | 95% Confidence Interval 11.2 to 16.5 | Months |
| Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Atezolizumab | TC1/2/3 or IC1/2/3-WT Population | 18.9 | 95% Confidence Interval 13.4 to 23.0 | Months |
| Progression-free Survival (PFS) in the TC3 or IC3-WT Populations | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 5.0 | 95% Confidence Interval 4.2 to 5.7 | Months | |
| Progression-free Survival (PFS) in the TC3 or IC3-WT Populations | Atezolizumab | 8.1 | 95% Confidence Interval 6.8 to 11.0 | Months | |
| Progression-free Survival (PFS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | TC2/3 or IC2/3-WT Population | 5.5 | 95% Confidence Interval 4.5 to 5.7 | Months |
| Progression-free Survival (PFS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations | Atezolizumab | TC2/3 or IC2/3-WT Population | 7.3 | 95% Confidence Interval 5.6 to 9.3 | Months |
1 to 10 of 741Source ClinicalTrials.gov
See all 741 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 287 | |
| Overall Study | STARTED | Atezolizumab | 285 | |
| Overall Study | COMPLETED | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 0 | |
| Overall Study | COMPLETED | Atezolizumab | 0 | |
| Overall Study | NOT COMPLETED | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 287 | |
| Overall Study | NOT COMPLETED | Atezolizumab | 285 |
Source ClinicalTrials.gov
Adverse events352
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 120 | 263 | 153 |
| other | Anaemia | Blood and lymphatic system disorders | Atezolizumab | 50 | 286 | 73 |
| other | Leukopenia | Blood and lymphatic system disorders | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 21 | 263 | 31 |
| other | Leukopenia | Blood and lymphatic system disorders | Atezolizumab | 4 | 286 | 6 |
| other | Neutropenia | Blood and lymphatic system disorders | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 71 | 263 | 128 |
| other | Neutropenia | Blood and lymphatic system disorders | Atezolizumab | 5 | 286 | 7 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 40 | 263 | 62 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Atezolizumab | 8 | 286 | 8 |
| other | Hypothyroidism | Endocrine disorders | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 3 | 263 | 3 |
| other | Hypothyroidism | Endocrine disorders | Atezolizumab | 27 | 286 | 28 |
1 to 10 of 352Source ClinicalTrials.gov
See all 352 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 211 | 287 |
| Total, all-cause mortality | Atezolizumab | 201 | 285 |
| Total, other adverse events | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 230 | 263 |
| Total, other adverse events | Atezolizumab | 238 | 286 |
| Total, serious adverse events | Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | 77 | 263 |
| Total, serious adverse events | Atezolizumab | 97 | 286 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) vs Atezolizumab: deaths from any cause | Trial comparisons |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) vs Atezolizumab: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02409342
GET https://conductscience.org/api/trials/v1/NCT02409342/registered?page=2